Charlotte Robinson

DocwireNews

Kianoush Makvandi and others observed that the Kidney Disease Improving Global Outcomes (KDIGO) classifications for evaluating the burden and impact of renal and cardiovascular (CV) adverse outcomes in patients with type 1 diabetes mellitus (T1DM) were underutilized. Therefore, they conducted a study to better understand: (1) the distribution of various KDIGO categories across the cohort, (2) the incidence of adverse renal and CV events for each category, and (3) the association of baseline KDIGO category and future excess risk for five major outcomes. Their results were presented at the 61st European Renal Association Congress.A total of 39,067 patients from the Swedish National Diabetes Register were included in the study, all of whom had T1DM. Based on their baseline albuminuria and creatinine, they were categorized into G1 to G5 estimated glomerular filtration rate (eGFR) and A1 to A3 albuminuria groups.Outcomes of interest for the study included acute kidney injury, 40% eGFR decline from baseline, kidney failure (KF), renal death, and a composite outcome of either of the preceding renal outcomes (MAKE). CV outcomes were also tracked and included coronary heart disease, stroke and CV death, and a composite outcome comprising either of the preceding CV outcomes and heart failure (MACE). The researchers also analyzed all-cause mortality.The researchers used Kaplan-Meier survival curves to assess cumulative incidence of outcomes, calculating the incidence rate per 1000 person-years. They used Cox proportional hazards regression risk models to study the association between baseline KDIGO category and the risk of five major outcomes: 40% eGFR decline, KF, MAKE, MACE, and all-cause mortality.The mean follow-up was 9.1 years (350,000 person-years). Chronic kidney disease (eGFR &lt;60 ml/min/1.73 m2 and/or albuminuria) was present in 18.5% of participants; 8.1% were normoalbuminuric. In both the increasing eGFR and albuminuria categories, there was a progressive increase in the incidence and adjusted hazard ratio for all outcomes. This was true even in subjects with eGFR &ge;60 ml/min/1.73 m2.Cox regression analyses were conducted referencing KDIGO categories combining G1A1 and G2A1 and then using only G1A1. Unexpectedly, repeat analysis using G1A1 alone found significantly elevated risk for all five major outcomes, even in G2A1, although this category normally would be considered low risk.In sum, the study authors wrote, &ldquo;A progressively increasing burden of adverse cardiorenal outcomes, including mortality, was observed with advancing KDIGO categories in [the] T1DM population. Even in subjects with preserved eGFR and normoalbuminuria, we identified an elevated risk for all major outcomes, indicating that early screening and implementation of preventive strategies may be beneficial in improving prognosis of this population.&rdquo;Source: Makvandi K, Eliasson B, Carlsen HK, Baid-Agrawal S. <a href="https://doi.org/10.1093/ndt/gfae069.1397" target="_blank" rel="noopener">Burden and excess risk of adverse outcomes in patients with type 1 diabetes utilizing KDIGO classification: a national cohort study.</a> Abstract #1750. Presented at the 61st European Renal Association Congress; May 23-26, 2024; Stockholm, Sweden.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Adverse Outcomes Across KDIGO Categories for Patients With T1DM

ERA Congress 2024

KDIGO classifications for evaluating the burden and impact of renal and cardiovascular (CV) adverse outcomes in type 1 diabetes are underutilized. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe